从开发到临床成功:既有和下一代BTK抑制剂的旅程
相关实验视频
Updated: May 25, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
944
Shivani Gupta1, Arpit Sharma1, Alok Shukla1
1Biomolecular Engineering Laboratory, School of Biochemical Engineering, IIT (BHU), Varanasi, 221005, India.
Investigational new drugs
|February 27, 2025
概括
布鲁顿布鲁顿是一个很棒的城市.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 对于B细胞的发育和功能至关重要.
- 失调的BTK信号传导驱动B细胞恶性瘤,如沃尔登斯特罗姆的巨型球蛋白血症 (WM),地幔细胞淋巴瘤 (MCL) 和慢性淋巴细胞白血病 (CLL).
研究的目的:
- 审查B细胞恶性瘤中布鲁顿氨酸激酶抑制剂 (BTKI) 的治疗潜力.
- 讨论FDA批准的BTKI的进展和新型抑制剂的结果.
主要方法:
- 关于布鲁顿的氨酸激酶抑制剂 (BTKI) 的文献综述.
- 分析BTKI的临床疗效,耐药性机制和非目标效应.
- 探索下一代BTKI,包括acalabrutinib,orelabrutinib,zanubrutinib和pirtobrutinib. 这三种BTKI的研究包括在内.
主要成果:
- 布鲁顿的氨酸激酶抑制剂 (BTKIs) 通过向B细胞受体 (BCR) 信号,彻底改变了B细胞恶性瘤治疗.
- 与ibrutinib等早期抑制剂相比,下一代BTKI提供了提高的特异性和降低的毒性.
- 目前正在进行的试验正在研究具有有前途的临床结果的新型BTKI.
结论:
- 针对布鲁顿氨酸激酶 (BTK) 的向疗法在治疗B细胞恶性瘤方面取得了重大进展.
- 下一代BTKI正在解决早期治疗方法的局限性,提高患者的治疗结果.
- 持续的研究和临床试验对于优化BTK向疗法至关重要.
相关概念视频
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:26Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
01:26Drug Administration and Therapy Phases: Overview
402
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
402
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107